Brean Capital Downgrades Endocyte To Hold

Analysts at Brean Capital downgraded Endocyte

from Buy to Hold. Endocyte shares have dropped 49.27% over the past 52 weeks, while the S&P 500 index has jumped 16.68% in the same period. Endocyte's shares fell 0.29% to $6.97 in pre-market trading.